Trends in Immunotherapy最新文献_第3页

Current mechanisms in the pathogenesis of lung fibrosis 当前肺纤维化的发病机制

Trends in Immunotherapy Pub Date : 2023-07-17 DOI: 10.24294/ti.v7.i1.2028

M. Engin, Ö. Özdemir

引用次数: 1

Revolutionizing cancer treatment by boosting dendritic cell vaccine efficacy with graphene oxide 用氧化石墨烯提高树突状细胞疫苗的效力，彻底改变癌症治疗

Trends in Immunotherapy Pub Date : 2023-07-17 DOI: 10.24294/ti.v7.i1.2039

Rafeezul Mohamed, M. M. Ramli, A. Reshak, N. Osman, M. Aziz, Mohd Syahir Mansor

引用次数: 1

Association of anticardiolipin antibodies with epilepsy in children 抗心磷脂抗体与儿童癫痫的关系

Trends in Immunotherapy Pub Date : 2023-07-03 DOI: 10.24294/ti.v7.i1.2021

S. Shiva, Shokoufeh Khanzadeh, Farzad Rashidi, B. Lucke-Wold

引用次数: 1

Screen natural terpenoids to identify potential Jab1 inhibitors for treating breast cancer 筛选天然萜类化合物以确定治疗乳腺癌的潜在Jab1抑制剂

Trends in Immunotherapy Pub Date : 2023-06-29 DOI: 10.24294/ti.v7.i1.2055

P. Pandey, Fahad Khan, K. Yadav, Kartikey Singh, Akhlakur Rehman, A. Mazumder, M. Khan

{"title":"Screen natural terpenoids to identify potential Jab1 inhibitors for treating breast cancer","authors":"P. Pandey, Fahad Khan, K. Yadav, Kartikey Singh, Akhlakur Rehman, A. Mazumder, M. Khan","doi":"10.24294/ti.v7.i1.2055","DOIUrl":"https://doi.org/10.24294/ti.v7.i1.2055","url":null,"abstract":"Jab1 (c-Jun activation domain-binding protein-1) overexpression has been extensively linked to cancer development (or metastasis) in various malignancies by positively regulating cancer cell proliferation or inactivating several tumor suppressors. Recent research has focused on utilizing plant products to target crucial elements of dysregulated signaling pathways to elucidate a potent cancer therapeutic approach. Terpenoids have shown significant anti-inflammatory and anti-cancerous properties in a broader range of carcinomas by inducing apoptosis. Through an extensive literature search, we have selected only those terpenoids (from the NPACT database) that have not been explored against Jab1 (CSN5, COP9 signalosome subunit 5) in breast cancer for our research study. We have used two docking servers, PATCH DOCK, and CB DOCK, to find the binding interaction between selected terpenoids and Jab1. Further, we have also used SWISS ADME to investigate the pharmacokinetics of selected ligands. Amongst all selected ligands, lutein (belongs to the xanthophylls class) has displayed maximum binding energy in both CB Dock and Patch Dock analysis. Hence, our preliminary in silico results have shown lutein as the potent lead candidate for developing a better drug against breast cancer. However, more in silico and in vitro studies are still needed to validate the inhibitory potential of lutein terpenoid against Jab1 in breast cancer.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124503729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Novel approaches for allergen-specific immunotherapy—An overview 过敏原特异性免疫治疗的新方法综述

Trends in Immunotherapy Pub Date : 2023-06-01 DOI: 10.24294/ti.v7.i1.2026

S. Sakshi, R. Mazumder, M. Monika, Neha Singh, B. Kumar

{"title":"Novel approaches for allergen-specific immunotherapy—An overview","authors":"S. Sakshi, R. Mazumder, M. Monika, Neha Singh, B. Kumar","doi":"10.24294/ti.v7.i1.2026","DOIUrl":"https://doi.org/10.24294/ti.v7.i1.2026","url":null,"abstract":"Allergen-specific immunotherapy (AIT) is an allergen-specific treatment for people with IgE-related allergies. Allergen-specific immunotherapy (AIT) is used to treat allergic disorders when symptoms persist despite medication and allergen avoidance. The therapy is presumed effective if it reduces the use of medications, improves the quality of life even after discontinuation of treatment, as well as prevents the conversion of one type of allergy to the other and the development of new sensitization. The allergen-specific immunotherapeutic agents can be administered sublingually, subcutaneously, or through some other routes, such as intra-lymphatically and epicutaneously to induce allergen tolerance by modifying immune responses (innate and adaptive). The primary mechanism of AIT is the induction of functional regulatory cells, such as regulatory T cells, follicular T cells, B cells, dendritic cells, innate lymphoid cells, and natural killer cells, which results in the control of the functions of type 2 inflammatory cells. However, there are several downsides to AIT, including the contentious treatment period resulting in high cost, systemic allergic reactions, and the lack of a biomarker for forecasting treatment responders. Vaccine adjuvants, adjunctive therapies, and novel vaccine technologies are currently being researched to address the issues associated with AIT. This article focuses on defined molecular approaches for improving the potential of specific immunotherapy that use recombinant allergen derivatives, allergen-derived peptides, virus-coupled allergens, nanoparticles, and specific adjuvants.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115539662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Development in therapeutic strategies for allergic conjunctivitis 过敏性结膜炎治疗策略的研究进展

Trends in Immunotherapy Pub Date : 2023-05-31 DOI: 10.24294/ti.v7.i1.2025

Neha Singh, R. Mazumder, M. Monika, S. Sakshi, Fahad Khan, B. Kumar

{"title":"Development in therapeutic strategies for allergic conjunctivitis","authors":"Neha Singh, R. Mazumder, M. Monika, S. Sakshi, Fahad Khan, B. Kumar","doi":"10.24294/ti.v7.i1.2025","DOIUrl":"https://doi.org/10.24294/ti.v7.i1.2025","url":null,"abstract":"Conjunctivitis, also known as pink eye, is a conjunctival inflammation. It is brought on by bacteria, viruses, toxins, and allergies, including coronaviruses, the most frequent reason being allergic conjunctivitis (AC), which is brought on by exposure to pollutants like pollen, animal hair, or mold. The primary contributor to it is the linkage of immunoglobulin E caused by allergens and receptors on stimulated conjunctival mast cells. As a consequence, mast cells are degranulated, along with the release of histamine, cytokines, chemokines, and lipid mediators. The particular eye tissues impacted and the immune mechanism(s) (both local and systemic) that are involved all play a role in the clinical course, length, intensity, and co-morbidities. It frequently occurs in conjunction with allergic rhinitis, also known as allergic rhino-conjunctivitis and other allergy conditions. Atopic keratoconjunctivitis, giant papillary conjunctivitis, seasonal and perennial conjunctivitis, and vernal keratoconjunctivitis are the different types of allergic conjunctivitis. Ocular allergies are frequently misdiagnosed and undertreated, despite the emergence of innovative therapeutic strategies. This review focuses on several previously published studies to discuss the available therapeutic options for treating allergic conjunctivitis as well as the potential targets for the therapies. The association of conjunctivitis with COVID-19, along with recent patents and research, has also been explored.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129200193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy 靶向ACE2受体的纳米药物:肺癌治疗的新途径

Trends in Immunotherapy Pub Date : 2023-01-14 DOI: 10.24294/ti.v7.i1.1838

Dillon Sivalingam, Moganavelli Singh

{"title":"Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy","authors":"Dillon Sivalingam, Moganavelli Singh","doi":"10.24294/ti.v7.i1.1838","DOIUrl":"https://doi.org/10.24294/ti.v7.i1.1838","url":null,"abstract":"The angiotensin-converting enzyme 2 (ACE2) receptor gained prominence in 2020, having been identified as a prime receptor for entry of the novel coronavirus COVID-19, which has led to the current global pandemic. Many studies have reported that lung cancer patients have a higher risk of contracting COVID-19 due to the up-regulated expression of ACE2 in lung cancer cells. Lung cancer is a heterogeneous disease and the most frequently occurring cancer globally. It is more prevalent in men than in women and accounts for an estimated 40% of cancer cases. Over the years, many studies have reported on the ACE2 expression in lung cancer. Conventional methods currently available for the detection and treatment of lung cancer face numerous challenges. Nanomedicine has risen to many challenges facing cancer therapy and drug delivery. With the array of nano delivery systems available, nanomedicine can be used to develop alternative methods to help overcome these challenges and improve the therapeutic efficiency in cancer therapy. Hence, this review focuses on lung cancer, the ACE2 receptor, and the use of nanomedicine in formulating a novel targeted cancer treatment strategy directed at the ACE2 receptor. This may serve as a stepping stone for exploring further targeting strategies and therapies.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126751909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Complement system as the potential therapeutic target in the management of COVID-19 patients 补体系统作为新冠肺炎患者治疗的潜在靶点

Trends in Immunotherapy Pub Date : 2022-12-27 DOI: 10.24294/ti.v6.i2.1834

Gilda Parsamanesh, Pooya Farhangnia, M. Karimi, Amirhossein Khosrozadeh Ghomi, Shiva Dehrouyeh, Azin Aghamajidi

引用次数: 0

Expressions of miR-199a-5p and miR-125b-5p and their target genes in the endometrium of recurrent implantation failure patients following in uterus infusion of autologous peripheral blood mononuclear cells 自体外周血单个核细胞子宫输注后复发性着床失败患者子宫内膜中miR-199a-5p、miR-125b-5p及其靶基因的表达

Trends in Immunotherapy Pub Date : 2022-12-22 DOI: 10.24294/ti.v6.i2.1457

Azita Azarpoor, A. Ardeshirylajimi, Samira Mohammadi-Yeganeh, Elham Pourmatrood, Z. Dehghan, Fattaneh Farifteh Nobijari, M. Salehi

{"title":"Expressions of miR-199a-5p and miR-125b-5p and their target genes in the endometrium of recurrent implantation failure patients following in uterus infusion of autologous peripheral blood mononuclear cells","authors":"Azita Azarpoor, A. Ardeshirylajimi, Samira Mohammadi-Yeganeh, Elham Pourmatrood, Z. Dehghan, Fattaneh Farifteh Nobijari, M. Salehi","doi":"10.24294/ti.v6.i2.1457","DOIUrl":"https://doi.org/10.24294/ti.v6.i2.1457","url":null,"abstract":"Despite numerous advances in fertility techniques, some individuals experience implantation failure. One of the therapeutic approaches is the study of immunological aspects of the implantation process in recurrent implantation failure (RIF) patients. Peripheral blood mononuclear cell (PBMC) therapy and platelet-rich plasma are currently available cell therapies. The aim of this study was to determine the expressions of the FGFR-2 and LIF genes that are regulated by miR-199a-5p and miR-125b-5p. These genes play a fundamental role in implantation in RIF patients treated with PBMCs. 20 patients clinically diagnosed with RIF were randomly assigned to a RIF patient with PBMCs intrauterine infusion group (n = 10) and RIF group (n = 10). Normal, healthy females (n = 10) comprised the control group. In order to examine the efficacy of the PBMCs injection in the treatment group, expressions of miR-199a-5p and miR-125-5p and FGFR-2 and LIF as their target genes, were evaluated in all three groups and were compared the results. We discovered that the RIF group had higher expressions of miR-199a-5p and miR-125-5p along with decreased expressions of their target genes. However, both FGFR-2 and LIF gene had elevated expressions in the RIF patients with PBMCs intrauterine infusion group compared to the RIF group, with significant decrease in miR-199a-5p and miR-125b-5p reciprocally. The treatment with PBMCs can be effective in changing the expression of microRNAs and genes associated with endometrial receptivity and by changes in the expression of them and their role during embryo development improve this process.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"393 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116668077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy for triple-negative breast cancer 三阴性乳腺癌的免疫疗法

Trends in Immunotherapy Pub Date : 2022-12-19 DOI: 10.24294/ti.v6.i2.1793

Yin A He, Xiaosheng Wang

引用次数: 10